文献速递牙周病口腔颌面外科

褪黑素与二甲双胍减轻多柔比星诱导的牙槽骨毒性

Melatonin and Metformin Mitigate Doxorubicin-Induced Alveolar Bone Toxicity.
PubMed 文献 · J Dent Res · 2024-08-05

研究在大鼠模型中观察多柔比星对牙槽骨稳态的损害,并比较多柔比星单用与联用褪黑素或二甲双胍的效果。结果显示多柔比星加重全身氧化应激、炎症和骨吸收并损害微结构与牙周状况,褪黑素在降低氧化应激、减少骨吸收及改善微结构和牙周状况方面优于二甲双胍。

要点

  • 多柔比星可损害牙槽骨微结构、促进骨吸收并恶化牙周状况。
  • 褪黑素在改善氧化应激、骨吸收、微结构和牙周状况方面优于二甲双胍。
  • 抗氧化剂尤其是褪黑素可能减轻化疗相关牙槽骨毒性。

核心结论

  • 褪黑素与二甲双胍均可部分改善多柔比星诱导的牙槽骨毒性,褪黑素在降低氧化应激、减少骨吸收及改善微结构和牙周状况方面更有效。
  • 抗氧化剂尤其是褪黑素具有改善多柔比星诱导牙槽骨毒性的潜力。

研究设计与样本

  • 雄性Wistar大鼠分为4组:对照组接受1 mL生理盐水,其余分别接受3 mg/kg多柔比星、3 mg/kg多柔比星加10 mg/kg褪黑素、3 mg/kg多柔比星加250 mg/kg二甲双胍。
  • 多柔比星于第0、4、8、15、22、29天给药,干预措施第0至29天每日给药,处死后采集血液与牙槽骨评估氧化应激、骨改建、炎症、微结构及牙周状况。

主要发现

  • 多柔比星增加全身氧化应激、降低抗氧化能力、增加炎症、减少骨形成、增加骨吸收、损害微结构并损害牙槽骨牙周状况。
  • 联用褪黑素或二甲双胍后上述指标均有部分改善。
  • 褪黑素在降低氧化应激、减少骨吸收、改善微结构和牙周状况方面优于二甲双胍。

临床怎么用

  • 对接受多柔比星化疗且存在牙周风险的患者,可关注抗氧化剂(尤其褪黑素)对牙槽骨毒性的潜在保护作用。
  • 该结果为动物实验证据,临床转化前需进一步研究验证。

局限性

  • 研究为雄性Wistar大鼠动物实验,样本分组与剂量有限,结果外推至人群需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Evidence concerning the osteotoxic effects of chemotherapy (doxorubicin) has been previously described. Periodontitis also progressively increases in patients receiving chemotherapy; however, the beneficial effects of melatonin and metformin on the alleviation of doxorubicin-induced osteotoxicity have never been investigated. Therefore, we investigated the negative impact of doxorubicin on alveolar bone homeostasis and the benefits of melatonin and metformin on the attenuation of doxorubicin-induced alveolar bone toxicity. Male Wistar rats were divided into 4 groups to receive either 1 mL of normal saline solution as a control group, 3 mg/kg of doxorubicin, 3 mg/kg of doxorubicin plus 10 mg/kg of melatonin, or 3 mg/kg of doxorubicin plus 250 mg/kg of metformin. Doxorubicin treatment was given on days 0, 4, 8, 15, 22, and 29, while interventions were given daily on days 0 to 29. Following euthanasia, blood and alveolar bones were collected for evaluation of oxidative stress, bone remodeling, inflammation, microarchitecture, and periodontal condition. We found that doxorubicin increased systemic oxidative stress, decreased antioxidative capacity, increased inflammation, decreased bone formation, increased bone reabsorption, impaired microarchitecture, and impaired periodontal condition of the alveolar bone. Although cotreatment with melatonin or metformin resulted in some improvement in these parameters, cotreatment with melatonin was more effective than cotreatment with metformin in terms of decreasing oxidative stress, reducing bone resorption, and improving microarchitecture and periodontal condition. All of these findings highlight the potential for antioxidants, especially melatonin, to ameliorate doxorubicin-induced alveolar bone toxicity.

来源:J Dent Res,查看原文。版权归原作者所有。

引用

  1. Srivichit B, Thonusin C, Aeimlapa R, et al. Melatonin and Metformin Mitigate Doxorubicin-Induced Alveolar Bone Toxicity. J Dent Res. 2024. PMID: 39101670. doi:10.1177/00220345241261980

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。